A. S. Evans

TL;DR: Examination of the clinical and environmental safety and immunogenicity in the first clinical trial of a live recombinant vaccinia virus expressing the E6 and E7 proteins of HPV 16 and 18 found vaccination resulted in no significant clinical side-effects and there was no environmental contamination by live TA-HPV.

TL;DR: In this paper, the authors identified HLA-A*0201-restricted peptide-specific CTLs in the peripheral blood (four of five patients), draining lymph nodes (three of four patients) and tumors (one of three patients) of cervical cancer patients.

TL;DR: This is the first demonstration that virus-specific CTLs infiltrate the virus-associated tumor, where they may play an important role in restricting disease progression.

TL;DR: It appears therefore feasible to induce HPV specific CTL responses in patients with cervical cancer using several vaccine strategies, however, further clinical trials are needed to determine the full anti-tumour potential of this vaccine based immunotherapy.

TL;DR: Presentation of the HPV16 E629–38 epitope in cervical carcinoma cell lines is limited both by the level of TAP expression and by the low level or availability of the source HPV E6 oncoprotein, which place constraints on the use of this, and potentially other, HPV-derived CTL epitopes for the immunotherapy of cervical cancer.